Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States
International Journal of Clinical Pharmacy · 2024-12 · 46 (6) · 1335-1344
DOI: 10.1007/s11096-024-01761-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 11.07.2024. Verfasst von Yingdan Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cost-Benefit Analysis, Lung Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Fujian Provincial Health Technology Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Although amivantamab has shown clinical benefits for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertions, its cost-effectiveness requires further investigation. AIM: To evaluate the cost-effectiveness of amivantamab plus chemotherapy for the treatment of NSCLC patients with EGFR exon 20 insertions from the United States payer perspective. METHOD: A partitioned survival model was developed based on the data from the PAPILLON trial. Costs were derived from the pricing files of Medicare and Medicaid Services and published literature, and utility values were derived from previous studies. A 3% annual discount rate was applied to both costs and outcomes. The primary outcome was the incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis, were conducted to test the model stability. RESULTS: Amivantamab plus chemotherapy yielded an additional 1.12 quality-adjusted life years (QALYs) while increasing costs by $483,769.50 relative to the chemotherapy regimen, leading to an ICER of $432,401.16/QALY. The combination of amivantamab with chemotherapy was not cost effective at a threshold of $150,000/QALY. In the scenario analysis, the results showed that the ICERs were $263,680.69/QALY and $418,416.35/QALY when different utility values and 10-year time horizons were adopted, respectively. For PSA, the probability that amivantamab plus chemotherapy would be cost-effective was 0% if the willingness-to-pay (WTP) threshold was $150,000/QALY. CONCLUSION: Amivantamab plus chemotherapy is unlikely to be a cost-effective option for NSCLC patients with EGFR exon 20 insertions. Reducing the cost of amivantamab may produce favorable economic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- International Research Center for Medicinal Administration, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, China.
- Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, 365000, China. xxwei0321@outlook.com.
ORCID-Profile: Yingdan Cao, Hongbin Yi, Fenghao Shi, Xiaoxia Wei, Sheng Han
Förderung
- Fujian Provincial Health Technology Project
Zitieren
APA
Cao, Y., Yi, H., Shi, F., Wei, X., & Han, S. (2024). Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States. International Journal of Clinical Pharmacy, 46(6), 1335-1344. https://doi.org/10.1007/s11096-024-01761-7
Vancouver
Cao Y, Yi H, Shi F, Wei X, Han S. Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States. International Journal of Clinical Pharmacy. 2024;46(6):1335-1344. doi:10.1007/s11096-024-01761-7
BibTeX
@article{Cao2024,
author = {Cao, Yingdan and Yi, Hongbin and Shi, Fenghao and Wei, Xiaoxia and Han, Sheng},
title = {Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States},
journal = {International Journal of Clinical Pharmacy},
year = {2024},
volume = {46},
number = {6},
pages = {1335--1344},
doi = {10.1007/s11096-024-01761-7}
}
EUVIMED